Immutep Targets New Cancer Trials After Manufacturing Differences Identified in Failed Study
IMM: $0.023 -4.17% · MC: $35M
Immutep says it has identified structural differences between the larger-scale efti used in discontinued TACTI-004 and the smaller-scale product used in earlier successful studies, and has contracted a new smaller-scale manufacturing run. The company intends to focus future registration-directed efti development on head and neck cancer and soft tissue sarcoma, with trial starts targeted for the second half of 2027; its cash runway is expected to extend well into the first half of 2028. Its soft tissue sarcoma trial met its primary endpoint, while IMP761 is now a co-priority alongside efti.

Comments